Details for Patent: 9,248,229

Which drugs does patent 9,248,229 protect, and when does it expire?

Patent 9,248,229 protects DILAUDID, DILAUDID-HP, and MORPHINE SULFATE, and is included in two NDAs.

This patent has fifteen patent family members in eleven countries.

Summary for Patent: 9,248,229

Title:	Packaging system for oxygen-sensitive drugs
Abstract:	Described herein are pharmaceutical packaging systems which prevent oxidative degradation of morphine, hydromorphone, promethazine and other oxygen-sensitive drugs, such systems including a syringe with an oxygen permeable tip cap, a hermetically sealed oxygen barrier blister packaging with very low permeability to oxygen and comprises ethylene vinyl, and an oxygen absorber.
Inventor(s):	Thomas DEVOUASSOUX, Eric FORAT, James Kenneth PROCTOR
Assignee:	Fresenius Kabi Deutschland GmbH
Application Number:	US14/207,207
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,248,229
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,248,229

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-006	Jan 16, 2020	AP	RX	Yes	Yes			Y
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-007	Feb 10, 2017	AP	RX	Yes	Yes			Y
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-003	Apr 30, 2009	AP	RX	Yes	Yes			Y
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-004	Apr 30, 2009	AP	RX	Yes	Yes			Y

International Family Members for US Patent 9,248,229

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014230836
Australia	2018236914
Brazil	112015022171
Canada	2902346